<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="Review Role of HIV Subtype Diversity in the Development of" exact="Resistance" post="to Antiviral Drugs WainbergMark A.*BrennerBluma G.[], bluma.brenner@mcgill.ca *Author to"/>
 <result pre="majority of reports on drug resistance deal with subtype B" exact="infections" post="in developed countries. However, both enzymatic and virological data"/>
 <result pre="naturally occurring polymorphisms among different nonB subtypes can affect HIV-1" exact="susceptibility to" post="antiretroviral drugs (ARVs), the magnitude of resistance conferred by"/>
 <result pre="resistance subtypes reverse transcriptase protease integrase 1. Introduction Most HIV" exact="infections" post="worldwide are due to non-subtype B infections [1]. HIV-1"/>
 <result pre="Introduction Most HIV infections worldwide are due to non-subtype B" exact="infections" post="[1]. HIV-1 group M has been classified into subtypes,"/>
 <result pre="areas of the genome (40% in the env gene) and" exact="lower" post="in others (8–10% in the pol, gag and IN"/>
 <result pre="sequences at positions associated with drug resistance mutations might predispose" exact="viral" post="isolates from different subtypes to encode different amino acid"/>
 <result pre="subtype C, D, A, and CRF02_AG infections, respectively, despite the" exact="absence of" post="pre-treatment resistance [10–13]. Ultrasensitive PCR detection procedures, which reveal"/>
 <result pre="studies on antiretroviral drug resistance in non-B subtypes exposed to" exact="chronic" post="suppressive therapy have yielded less definitive results with respect"/>
 <result pre="in defining inter-subtype differences. While genotyping can classify the major" exact="viral" post="subtypes, significant proportions (∼15%) of infections remain unassigned or"/>
 <result pre="can classify the major viral subtypes, significant proportions (∼15%) of" exact="infections" post="remain unassigned or differentially assigned using different subtyping algorithms"/>
 <result pre="ARV therapy, the high cost of drug resistance testing and" exact="limited" post="opportunities for research in resource-limited areas. Furthermore, resistance tests"/>
 <result pre="but not in general practice. 2. Results and Discussion 2.1." exact="Resistance" post="to Nucleoside Reverse Transcriptase Inhibitors (NRTIs) In Botswana, subtype"/>
 <result pre="In Botswana, subtype C patients treated with ZDV/ddI developed an" exact="atypical" post="thymidine analogue resistance pathway (67N/70R/215Y) compared to subtype B"/>
 <result pre="analogue mutations (TAMs) could be ascribed to treatment regimen and" exact="disease" post="stage [24–27]. Access to viral load testing lead in"/>
 <result pre="ascribed to treatment regimen and disease stage [24–27]. Access to" exact="viral" post="load testing lead in India was associated with early"/>
 <result pre="generation of D67N and TAMs rather than K65R pathways [37–39]." exact="Advanced" post="ultra-deep pyrosequencing (UDPS) techniques have been used to detect"/>
 <result pre="minority species in treatment-naïve populations [40–41]. Patients harboring subtype C" exact="infections" post="showed a higher frequency of K65R than subtype B"/>
 <result pre="UDPS but these differences were not replicated using limiting dilution" exact="clonal" post="sequencing approaches [40]. The discrepant UDPS findings are consistent"/>
 <result pre="has been associated with the Y181C nevirapine mutation within the" exact="viral" post="backbone [30,42]. Drug resistance selection studies showed that subtype"/>
 <result pre="ddI and d4T-containing regimens, as well as Y181C in the" exact="viral" post="backbone. Thymidine analogue pathways are favored with zidovudine-based regimens."/>
 <result pre="for the preferred selection of K65R in subtype C. 2.2." exact="Resistance" post="to Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs) Tissue culture selection"/>
 <result pre="use in subtype B [52–53]. A third study reported an" exact="absence of" post="the D30N mutation in CRF01_AE, but no information on"/>
 <result pre="[64]. An observational study from southern Brazil also showed a" exact="lower" post="relative frequency of primary resistance to PIs in subtype"/>
 <result pre="from southern Brazil also showed a lower relative frequency of" exact="primary" post="resistance to PIs in subtype C as compared to"/>
 <result pre="former subtype [65]. In general, HIV-1 subtype diversity has not" exact="limited" post="the overall benefit of ART (Table 1). However, there"/>
 <result pre="are associated with NNRTI resistance in subtype B and may" exact="lower" post="the resistance barrier and duration of efficacy of NNRTIs"/>
 <result pre="it does not involve new mutations. One study reported a" exact="lower" post="risk for accumulation of major (primary) resistance mutations in"/>
 <result pre="PIs. Thus, it makes sense that there might be a" exact="lower" post="accumulation of major mutations in C subtypes, if we"/>
 <result pre="similarly in subtype C as they do when present as" exact="secondary" post="resistance mutations in subtype B. Overall, the majority of"/>
 <result pre="pocket of A/G proteases appear to be responsible for a" exact="lower" post="binding energy of NFV and hence lower susceptibility of"/>
 <result pre="responsible for a lower binding energy of NFV and hence" exact="lower" post="susceptibility of A/G viruses to this drug [70]. Others"/>
 <result pre="this drug [70]. Others have also found A/G isolates with" exact="lower" post="susceptibilities to certain PIs (NFV and ATV). Only one"/>
 <result pre="study has detected an important proportion of WT isolates with" exact="lower" post="susceptibilities to ATV [71]. Most phenotypes have been determined"/>
 <result pre="performed on target-inhibitor interactions in PR have specifically described a" exact="lower" post="affinity of non-B subtype proteases for PIs and amplification"/>
 <result pre="affinity of non-B subtype proteases for PIs and amplification of" exact="primary" post="resistance mutations on the basis of background polymorphisms. Few"/>
 <result pre="C instead of D30N. Competition assays appear to support a" exact="lower" post="fitness of subtype C viruses bearing D30N, which could"/>
 <result pre="explain the above findings [61]. 2.4. Implications for Clinical Practice" exact="Resistance" post="in non- B subtypes has rarely been reported on"/>
 <result pre="background can affect the degree of protein binding caused by" exact="primary" post="mutations and restore the function of protease (PR) to"/>
 <result pre="in each subtype. This effect was not discernible in the" exact="absence of" post="typical major resistance mutations, but rather when particular backgrounds"/>
 <result pre="In this regard, some background polymorphisms can clearly act as" exact="secondary" post="resistance mutations. HIV phenotypic assays have failed to find"/>
 <result pre="because many polymorphisms in non-B viruses are considered to be" exact="secondary" post="resistance mutations based on the fact that they emerge"/>
 <result pre="effect or hypersensitize HIV to ARVs, e.g., I93L is a" exact="secondary" post="resistance mutation in subtype B but causes hypersusceptibility to"/>
 <result pre="mutually reinforcing intracellular half-lives that act in combination to suppress" exact="viral" post="replication and prevent the emergence of resistance mutations. However,"/>
 <result pre="subtype C in the emergence of K65R in clinical settings." exact="Multiple" post="clinical and in vitro studies have confirmed that protease"/>
 <result pre="as compensatory substitutions that may increase levels of resistance and" exact="viral" post="replication capacity. None of the recombinant phenotyping systems used"/>
 <result pre="[8]. The potential of cross-resistance acquires importance in settings with" exact="limited" post="access to antiretroviral therapy. Few in vitro comparative data"/>
 <result pre="in humansNat Rev Microbiol2007514115117203103 2.SoaresEASantosRPPellegriniJASprinzETanuriASoaresMAEpidemiologic and molecular characterization of human" exact="immunodeficiency" post="virus type 1 in southern BrazilJ Acquir Immune Defic"/>
 <result pre="Rev Microbiol2007514115117203103 2.SoaresEASantosRPPellegriniJASprinzETanuriASoaresMAEpidemiologic and molecular characterization of human immunodeficiency virus" exact="type 1" post="in southern BrazilJ Acquir Immune Defic Syndr20033452052614657764 3.SoaresEAMartinezAMSouzaTMSantosAFDa HoraVSilveiraJBastosFITanuriASoaresMAHIV-1"/>
 <result pre="dissemination in southern BrazilAIDS200519Suppl. 4S81S8616249660 4.BrennanCABritesCBodellePGoldenAHackettJJrHolzmayerVSwansonPVallariAYamaguchiJDevareSet al.HIV-1 strains identified in" exact="Brazilian" post="blood donors: significant prevalence of B/F1 recombinantsAIDS Res Hum"/>
 <result pre="sentinel survey of antiretroviral drug resistance in patients with HIV-1" exact="primary" post="infection and in antiretroviral-naive chronically infected patients in 2001–2002J"/>
 <result pre="survey of antiretroviral drug resistance in patients with HIV-1 primary" exact="infection" post="and in antiretroviral-naive chronically infected patients in 2001–2002J Acquir"/>
 <result pre="infected patients in 2001–2002J Acquir Immune Defic Syndr20053854555215793364 8.BrennerBGResistance and" exact="viral" post="subtypes: how important are the differences and why do"/>
 <result pre="Dis20061959460617075337 10.ToniTDMasquelierBLazaroEDore-MbamiMBa-GomisFOTea-DiopYKouakouKDibyJSiaESoppiSet al.Characterization of nevirapine (NVP) resistance mutations and HIV" exact="type 1" post="subtype in women from Abidjan (Cote d'Ivoire) after NVP"/>
 <result pre="from Abidjan (Cote d'Ivoire) after NVP single-dose prophylaxis of HIV" exact="type 1" post="mother-to-child transmissionAIDS Res Hum Retrovirus20052110311034 11.EshlemanSHHooverDRChenSHudelsonSEGuayLAMwathaAFiscusSAMmiroFMusokePJacksonJBet al.Nevirapine (NVP) resistance"/>
 <result pre="al.Comparison of HIV-1 mother-to-child transmission after single-dose nevirapine prophylaxis among" exact="African" post="women with subtypes A, C, and DJ Acquir Immune"/>
 <result pre="review of virologic and biochemical evidenceAIDS Rev20081021222319092977 18.DescampsDCollinGLetourneurFApetreiCDamondFLoussert-AjakaISimonFSaragostiSBrun-VezinetFSusceptibility of human" exact="immunodeficiency" post="virus type 1 group O isolates to antiretroviral agents:"/>
 <result pre="virologic and biochemical evidenceAIDS Rev20081021222319092977 18.DescampsDCollinGLetourneurFApetreiCDamondFLoussert-AjakaISimonFSaragostiSBrun-VezinetFSusceptibility of human immunodeficiency virus" exact="type 1" post="group O isolates to antiretroviral agents: in vitro phenotypic"/>
 <result pre="antiretroviral agents: in vitro phenotypic and genotypic analysesJ Virol199771889388989343254 19.TuaillonEGueudinMLemeeVGueitIRoquesPCorriganGEPlantierJCSimonFBraunJPhenotypic" exact="susceptibility to" post="nonnucleoside inhibitors of virion-associated reverse transcriptase from different HIV"/>
 <result pre="in rural South AfricaAIDS2008222210221218832885 25.DeshpandeAJauvinVMagninNPinsonPFaureMMasquelierBAurillac-LavignolleVFleuryHJResistance mutations in subtype C HIV" exact="type 1" post="isolates from Indian patients of Mumbai receiving NRTIs plus"/>
 <result pre="Mumbai receiving NRTIs plus NNRTIs and experiencing a treatment failure:" exact="Resistance" post="to ARAIDS Res Hum Retrovirus200723335340 26.HosseinipourMCvan OosterhoutJJWeigelRPhiriSKamwendoDParkinNFiscusSANelsonJAEronJJKumwendaJThe public health"/>
 <result pre="Dis2008461589159718419495 28.Doualla-BellFAvalosABrennerBGaolatheTMineMGaseitsiweSOliveiraMMoisiDNdwapiNMoffatHet al.High prevalence of the K65R mutation in human" exact="immunodeficiency" post="virus type 1 subtype C isolates from infected patients"/>
 <result pre="al.High prevalence of the K65R mutation in human immunodeficiency virus" exact="type 1" post="subtype C isolates from infected patients in Botswana treated"/>
 <result pre="immunological WHO guidelinesAIDS Res Hum Retrovirus201026343350 33.AyeleWMekonnenYMesseleTMengistuYTsegayeABakkerMBerkhoutBDorigo-ZetsmaWWoldayDGoudsmitJet al.Differences in HIV" exact="type 1" post="RNA plasma load profile of closely related cocirculating Ethiopian"/>
 <result pre="K65R reverse transcriptase mutation in subtype C variants of human" exact="immunodeficiency" post="virus type 1J Virol2009832029203319073730 38.CoutsinosDInvernizziCFXuHBrennerBGWainbergMAFactors affecting template usage in"/>
 <result pre="transcriptase mutation in subtype C variants of human immunodeficiency virus" exact="type 1J" post="Virol2009832029203319073730 38.CoutsinosDInvernizziCFXuHBrennerBGWainbergMAFactors affecting template usage in the development of"/>
 <result pre="resistance mutationPLoS One20105e1099220539818 41.D'AquilaRTGerettiAMHortonJHRouseEKheshtiARaffantiSOieKPappaKRossLLTenofovir (TDF)-Selected or Abacavir (ABC)-Selected Low-Frequency HIV" exact="Type 1" post="Subpopulations during Failure with Persistent Viremia as Detected by"/>
 <result pre="(TDF)-Selected or Abacavir (ABC)-Selected Low-Frequency HIV Type 1 Subpopulations during" exact="Failure" post="with Persistent Viremia as Detected by Ultradeep PyrosequencingAIDS Res"/>
 <result pre="Res Hum Retrovirus201010.1089/aid.2010.0077. 42.ZolfoMSchapiroJPhanVKooleOThaiSVekemansMFransenKLynenLGenotypic impact of prolonged detectable HIV-1 RNA" exact="viral" post="load after HAART failure in a CRF01_AE infected cohortAIDS"/>
 <result pre="Burkina FasoJ Acquir Immune Defic Syndr200849172518667925 45.LoembaHBrennerBParniakMAMa'ayanSSpiraBMoisiDOliveiraMDetorioMWainbergMAGenetic divergence of human" exact="immunodeficiency" post="virus type 1 Ethiopian clade C reverse transcriptase (RT)"/>
 <result pre="Acquir Immune Defic Syndr200849172518667925 45.LoembaHBrennerBParniakMAMa'ayanSSpiraBMoisiDOliveiraMDetorioMWainbergMAGenetic divergence of human immunodeficiency virus" exact="type 1" post="Ethiopian clade C reverse transcriptase (RT) and rapid development"/>
 <result pre="associated with antiretroviral drug treatment failure in CRF01_AE (subtype E)" exact="infection" post="differ from subtype B infectionJ Acquir Immune Defic Syndr20033333634212843744"/>
 <result pre="from subtype B infectionJ Acquir Immune Defic Syndr20033333634212843744 53.ChaixMLRouetFKouakoussuiKALaguideRFassinouPMontchoCBlancheSRouziouxCMsellatiPGenotypic human" exact="immunodeficiency" post="virus type 1 drug resistance in highly active antiretroviral"/>
 <result pre="B infectionJ Acquir Immune Defic Syndr20033333634212843744 53.ChaixMLRouetFKouakoussuiKALaguideRFassinouPMontchoCBlancheSRouziouxCMsellatiPGenotypic human immunodeficiency virus" exact="type 1" post="drug resistance in highly active antiretroviral therapy-treated children in"/>
 <result pre="d'IvoirePediatr Infect Dis J2005241072107616371868 54.SukasemCChurdboonchartVSukeepaisarncharoenWPirojWInwisaiTTiensuwanMChantratitaWGenotypic resistance profiles in antiretroviral-naive HIV-1" exact="infections" post="before and after initiation of first-line HAART: Impact of"/>
 <result pre="Agents20083127728118182278 55.GrossmanZPaxinosEEAverbuchDMaayanSParkinNTEngelhardDLorberMIstominVShakedYMendelsonEet al.Mutation D30N is not preferentially selected by human" exact="immunodeficiency" post="virus type 1 subtype C in the development of"/>
 <result pre="al.Mutation D30N is not preferentially selected by human immunodeficiency virus" exact="type 1" post="subtype C in the development of resistance to nelfinavirAntimicrob"/>
 <result pre="of resistance to nelfinavirAntimicrob Agents Chemother2004482159216515155216 56.Doualla-BellFAvalosAGaolatheTMineMGaseitsiweSNdwapiNNovitskyVABrennerBOliveiraMMoisiDet al.Impact of human" exact="immunodeficiency" post="virus type 1 subtype C on drug resistance mutations"/>
 <result pre="to nelfinavirAntimicrob Agents Chemother2004482159216515155216 56.Doualla-BellFAvalosAGaolatheTMineMGaseitsiweSNdwapiNNovitskyVABrennerBOliveiraMMoisiDet al.Impact of human immunodeficiency virus" exact="type 1" post="subtype C on drug resistance mutations in patients from"/>
 <result pre="failing a nelfinavir-containing regimenAntimicrob Agents Chemother2006502210221316723586 57.DumansATSoaresMAMachadoESHueSBrindeiroRMPillayDTanuriASynonymous genetic polymorphisms within" exact="Brazilian" post="human immunodeficiency virus Type 1 subtypes may influence mutational"/>
 <result pre="nelfinavir-containing regimenAntimicrob Agents Chemother2006502210221316723586 57.DumansATSoaresMAMachadoESHueSBrindeiroRMPillayDTanuriASynonymous genetic polymorphisms within Brazilian human" exact="immunodeficiency" post="virus Type 1 subtypes may influence mutational routes to"/>
 <result pre="Agents Chemother2006502210221316723586 57.DumansATSoaresMAMachadoESHueSBrindeiroRMPillayDTanuriASynonymous genetic polymorphisms within Brazilian human immunodeficiency virus" exact="Type 1" post="subtypes may influence mutational routes to drug resistanceJ Infect"/>
 <result pre="on in vitro phenotype, fitness, and replication capacity of human" exact="immunodeficiency" post="virus type 1 with subtype B and C proteasesAntimicrob"/>
 <result pre="vitro phenotype, fitness, and replication capacity of human immunodeficiency virus" exact="type 1" post="with subtype B and C proteasesAntimicrob Agents Chemother2004483552355515328124 62.KantorRKatzensteinDPolymorphism"/>
 <result pre="West AfricaClin Infect Dis20094847648319143530 68.NtemgwaMLd’Aquin ToniTBrennerBGCamachoRJWainbergMAAntiretroviral drug resistance in human" exact="immunodeficiency" post="virus type 2Antimicrob Agents Chemother2009533611361919470514 69.SyllaMChamberlandABoileauCTraoreHAAg-AboubacrineSCisseMKoalaSDraboJDialloINiambaPet al.Characterization of drug"/>
 <result pre="and Burkina FasoAntivir Ther20081314114818389909 70.KinomotoMAppiah-OpongRBrandfulJAYokoyamaMNii-TrebiNUgly-KwameESatoHOfori-AdjeiDKurataTBarre-SinoussiFet al.HIV-1 proteases from drug-naive West" exact="African" post="patients are differentially less susceptible to protease inhibitorsClin Infect"/>
 <result pre="drug resistance mutations by background polymorphisms in HIV-1 protease from" exact="African" post="subtypesBiochemistry2002418613861912093278 73.NachegaJBHislopMDowdyDWChaissonRERegensbergLMaartensGAdherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy"/>
 <result pre="antiretroviral resistance in treated Ugandans infected with non-subtype B human" exact="immunodeficiency" post="virus type 1AIDS Res Hum Retrovirus200420355364 75.XuHTMartinez-CajasJLNtemgwaMLCoutsinosDFrankelFABrennerBGWainbergMAEffects of the"/>
</results>
